Citi resumed coverage of Sensei Biotherapeutics with a Buy rating and $4 price target after a period of the firm's rating being suspended. Sensei presented dose-escalation efficacy data for SNS-101 monotherapy and in combination with Libtayo at ASCO and, while early, the data appear to demonstrate preliminary signals of clinical activity, the analyst tells investors. The firm continues to see potential for SNS-101 across multiple tumor types and anticipates additional data later this year will begin to clarify SNS-101's clinical potential, the analyst added.